Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of preservative-free tafluprost versus preservative-free timolol in open-angle glaucoma or ocular hypertension
2009-015798-11Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing Preservative-free tafluprost with Preservative-free timolol maleate (2 arms). Primary endpoint: Mean change in intraocular pressure from baseline. Started Mar 2010; status: completed.
02
Drugs
tafluprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2009-015798-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015798-11.